Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

被引：35
|
作者：
Jafari, S. Morteza Seyed [1 ]
Feldmeyer, Laurence [1 ]
Bossart, Simon [1 ]
Simon, Dagmar [1 ]
Schlapbach, Christoph [1 ]
Borradori, Luca [1 ]
机构：
[1] Univ Bern, Univ Hosp Bern, Inselspital, Dept Dermatol, Bern, Switzerland
来源：
FRONTIERS IN IMMUNOLOGY | 2021年 / 11卷
关键词：
bullous pemphigoid; dupilumab; omalizumab; recalcitrant; treatment;
D O I：
10.3389/fimmu.2020.611549
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Use of dupilumab for recalcitrant bullous pemphigoid: A case report
    Lamb, Jillian
    Purdy, Kerri
    Sutherland, Ashley
    [J]. SAGE OPEN MEDICAL CASE REPORTS, 2024, 12
  • [2] Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid
    Kaye, Alex
    Gordon, Samantha C.
    Deverapalli, Sandhya C.
    Her, Min Ji
    Rosmarin, David
    [J]. JAMA DERMATOLOGY, 2018, 154 (10) : 1225 - 1226
  • [3] Case report: Dupilumab for the treatment of bullous pemphigoid
    Wang, Mengxin
    Wang, Juan
    Shi, Bingjun
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [4] Case Report: Omalizumab Successfully Treated Recalcitrant Bullous Pemphigoid in an Elderly Patient with Multiple Comorbidities
    Liu, Jue
    Xiang, Tingkai
    Wang, Wei
    Bu, Zhangyu
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 : 1391 - 1396
  • [5] Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review
    Granados-Betancort, Elena
    Sanchez-Diaz, Manuel
    Munoz-Barba, Daniel
    Arias-Santiago, Salvador
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [6] Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid
    Le, Stephanie T.
    Herbert, Samantha
    Haughton, Renee
    Nava, Jordan
    Toussi, Atrin
    Ji-Xu, Antonio
    Maverakis, Emanual
    [J]. JAMA DERMATOLOGY, 2024, 160 (01) : 107 - 109
  • [7] Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review
    Cao, Peng
    Xu, Wenjing
    Zhang, Litao
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid
    Margiotta, Flavia Manzo
    Fidanzi, Cristian
    Bevilacqua, Matteo
    Janowska, Agata
    Marco, Romanelli
    Manni, Elisabetta
    [J]. SKIN RESEARCH AND TECHNOLOGY, 2023, 29 (10)
  • [9] Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report
    Liu, Jing-Hua
    Gao, Qian
    Ma, Wen-Yi
    Cheng, Zi-Lin
    Luo, Na-Na
    Hao, Ping-Sheng
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 1583 - 1587
  • [10] Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report
    Pop, Samantha R.
    Strock, Daniel
    Smith, Robert J.
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (08)
12345